Date: Wednesday, September 11 at 1PM CT / 2PM ET

SkunkWorx Bio, has developed a new generation of precision therapeutics that it terms SKWX proteins and SKWX antibodies. They are derived from the Company’s unique drug discovery platforms based on a suite of integrated technology modules using naturally occurring templates or rationally designed constructs. SkunkWorx has 3 cornerstones that drive versatility and allow flexibility in the selection and development of its innovative precision biologics: 1). Random display libraries which allow us to identify novel small proteins and fully human single domain antibodies; 2). An approach, termed Designed Engineering, which dramatically enhances the generation, diversity and performance of therapeutic single domain antibodies; and 3). The development of bi-specific drug conjugates, called SPDCs (Small Protein Drug Conjugates), which combine target-specific internalizing small proteins and antibodies to both drugs and biological inhibitors. These integrated platforms differentiate SkunkWorx from other companies pursuing alternatives to classical antibody-based and ADC therapeutics.
Key Learnings:
1.Using high diversity randomized display libraries to identify novel agonists and antagonists for both known and "undruggable' disease-related targets
2.Developing novel small protein-drug conjugates for treating cancer and other diseases
3.Developing novel single domain antibodies for treating cancer and other diseases

Register for their webinar to discuss all these and more here